| Name | Title | Contact Details |
|---|
United Cerebrial Palsy is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Idenix Pharmaceuticals, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Idenix Pharmaceuticals, Inc. is based in Cambridge, MA. You can find more information on Idenix Pharmaceuticals, Inc. at www.idenix.com
For more than 20 years, Fortus Healthcare Resources has embraced a personalized approach to recruiting. With a candidate database unmatched in the industry, we value our relationship with clients and candidates. The Fortus Group is the pioneer of dialysis recruitment. Since 1993, we have been committed to providing recruitment solutions for the dialysis industry with much success and growth. Our organization has expanded from a one-desk specialty recruiter to a state-of-the-art facility. With a staff of over 30, we continue to maintain the largest recruiting staff industrywide. Our company`s 100+ years combined dialysis recruiting experience enables us to provide the best possible means for candidates to fulfill their goals. In 2006, our services expanded from permanent placement of dialysis and transplantation professionals to the placement of travel nurses. With flexible, competitive salary and benefit packages, Fortus Group Travel offers the healthcare industry temporary staffing relief, while providing nurses with unlimited travel opportunities. The Fortus Group continues to build on its strong foundation of quality resources and dedicated relationships. The success of our company is based on bringing together the highest quality career consultants dedicated to providing outstanding opportunities to our specialized industry.
Bosom Buddies of Georgia Inc is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.